PRR Share Price

Open 0.04 Change Price %
High 0.04 1 Day 0.00 0.00
Low 0.04 1 Week 0.00 0.00
Close 0.04 1 Month 0.00 0.00
Volume 657718 1 Year -0.01 -20.00
52 Week High 0.06
52 Week Low 0.03
PRR Important Levels
Resistance 2 0.04
Resistance 1 0.04
Pivot 0.04
Support 1 0.04
Support 2 0.04
ASX Australia Most Active Stocks
AGO 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
TEG 0.05 0.00%
TEG 0.05 0.00%
TEG 0.05 0.00%
AKK 0.01 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
IMU 0.02 100.00%
IMU 0.02 100.00%
PMQ 0.03 50.00%
ARD 0.03 50.00%
ARD 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
EXG 0.03 50.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
AVD 0.01 -50.00%
AVD 0.01 -50.00%
AVD 0.01 -50.00%
SRX 16.00 -37.23%
SRX 16.00 -37.23%
More..

Prima Biomed Ltd (ASX: PRR)

PRR Technical Analysis 2
As on 9th Dec 2016 PRR Share Price closed @ 0.04 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.04 & Strong Buy for SHORT-TERM with Stoploss of 0.04 we also expect STOCK to react on Following IMPORTANT LEVELS.
PRR Target for December
1st Target up-side 0.05
2nd Target up-side 0.05
3rd Target up-side 0.05
1st Target down-side 0.03
2nd Target down-side 0.03
3rd Target down-side 0.03
PRR Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.primabiomed.com.au
PRR Address
PRR
151 Macquarie Street
Level 7
Sydney, NSW 2000
Australia
Phone: 61 2 9276 1224
Fax: 61 2 9276 1284
PRR Latest News
Interactive Technical Analysis Chart Prima Biomed Ltd ( PRR ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Prima Biomed Ltd
PRR Business Profile
Prima BioMed Ltd., a biotechnology company, researches, develops, and commercializes licensed medical biotechnology products in Australia. Its lead product includes CVac, a cancer vaccine for patients in remission, which has completed two human clinical trials. The company is also developing oral vaccine against human papilloma virus, a virus associated with development of cervical cancer. Prima BioMed Ltd. is based in Sydney, Australia.